Utility of biomarkers in the diagnosis and monitoring of asthmatic children.

"Declaration of competing interest PX discloses consultancy awards received from Nutricia, Nestle, Friesland, Uriach and 10.13039/100004336Novartis, though unrelated to this work. YA received speaker fees or honoraria for advisory boards by 10.13039/100004339Sanofi, MSD, 10.13039/100004336Novartis, GSK, 10.13039/501100003769Eisai, Kyorin Pharmaceutical, 10.13039/501100010486Teijin Pharma, Torii Pharmaceutical, and 10.13039/501100007132Otsuka Pharmaceutical, though unrelated to this work. RMG received grant support, speaker fees or honoraria by GSK, 10.13039/100004336Novartis, Nutricia, Stallergenes and 10.13039/100004339Sanofi, none of them related to this work. AN has received grant support, speaker fees or honoraria for advisory boards by Diater, GSK, Inmunotek, Menarini, MSD, 10.13039/100004336Novartis, Nutricia, Ordesa and Uriach though unrelated to this work. 10.13039/100016049WP received consultant fees from GSK, 10.13039/100004336Novartis, 10.13039/100009857Regeneron, 10.13039/100004328Genentech, 10.13039/100004339Sanofi, Teva and grant support from GSK, 10.13039/100004336Novartis, 10.13039/100004328Genentech, 10.13039/100009857Regeneron, and 10.13039/100004334Merck on asthma therapeutics. NGPhas received grant support, speaker fees or honoraria for advisory boards by Astra Zeneca, 10.13039/100001003Boehringer Ingelheim, Biomay, GSK, HAL, 10.13039/100016259Mylan, Menarini, MSD, 10.13039/100004336Novartis, Nutricia, and 10.13039/100004339Sanofi, though unrelated to this work. ZAE, CFPB, EH, IF, MM, PP, GWKW declare no competing interests."

"Funding Not applicable."